NW
NWCI.US NewCardio Inc
- Market cap
- USD 3.31K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2011.
Is NWCI.US undervalued?
Graham numberThe Graham number of NewCardio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NewCardio Inc fundamental analysis
No fundamental analysis for NewCardio Inc yet.
NewCardio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NewCardio Inc
NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead …
Full company profileNewCardio Inc financial statements
2011 annualized: Fiscal year 2011 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2011, the balance sheet is the latest quarter. Figures change when the annual report is published.
NewCardio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2007 | 2008 | 2009 | 2010 | 2011 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 257K | 201K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 105K | 33.9K |
| Operating Income | -2.10M | -7.83M | -10.0M | -9.46M | -7.02M |
| Net Income | -3.19M | -14.2M | -9.59M | -11.5M | -7.50M |
| Balance Sheet | |||||
| Total Assets | 6.48M | 4.72M | 2.30M | 2.85M | 240K |
| Total Liabilities | 5.68M | 1.60M | 2.99M | 6.01M | 5.77M |
| Shareholders' Equity | 800K | 3.12M | -689K | -3.16M | -5.53M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | |||||
| Operating Cash Flow | -1.13M | -4.69M | -5.65M | -4.56M | -2.53M |
| Capital Expenditure | 8.28K | 122K | 148K | 37.2K | 4.53K |
| Ratios | |||||
| ROE | -398.3% | -454.1% | - | - | - |
| ROA | -49.1% | -300.5% | -416.7% | -402.9% | -3,123.1% |
| Net Profit Margin | - | - | - | -4,466.3% | -3,739.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NewCardio Inc dividends
NewCardio Inc has not paid dividends in the last 4 fiscal years.
Who owns NewCardio Inc
Ownership data of NewCardio Inc is not available yet.
NewCardio Inc company profile
- Company name
- NewCardio Inc
- Ticker
- NWCI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 10
- Fiscal year end
- December
- Address
- PO Box 658, Branchburg, NJ, United States, 08853
- Phone
- 877 332 4324
- Website
- -
About NewCardio Inc
NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes. Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data. The company is also developing my3KG, a software application to provide a method to assess cardiac electrical activity in time and space. NewCardio, Inc. was founded in 2004 and is based in Branchburg, New Jersey.
NewCardio Inc management
2- Dr. Jess Emery Jones M.D.CEO & Director · born 1979
- Mr. Greg SadowskiChief Operating Officer